Alefacept, a fusion protein approved for psoriasis, has been trialled in patients with new-onset type 1 diabetes mellitus. However, the withdrawal of the drug from the US market and the unmet primary end point do not raise hope for this drug, even though some secondary end points were met and the study highlighted interesting immunological efficacy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stiller, C. R. et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223, 1362–1367 (1984).
Assan, R. et al. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1, 67–71 (1985).
Chatenoud, L., Warncke, K. & Ziegler, A. G. Clinical immunologic interventions for the treatment of type 1 diabetes. Cold Spring Harb. Perspect. Med. 2, 1–18 (2012).
Rigby, M. R. et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/S2213-8587(13)70111-6.
Gordon, K. B. & Langley, R. G. Remittive effects of intramuscular alefacept in psoriasis. J. Drugs Dermatol. 2, 624–628 (2003).
Krueger, G. G. Selective targeting of T cell subsets: focus on alefacept—a remittive therapy for psoriasis. Expert Opin. Biol. Ther. 2, 431–441 (2002).
Greenbaum, C. J. et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 61, 2066–2073 (2012).
Palmer, J. P. et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes 53, 250–264 (2004).
Herold, K. C. et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes http://dx.doi.org/10.2337/db13-0345.
Steele, C. et al. Insulin secretion in type 1 diabetes. Diabetes 53, 426–433 (2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Buzzetti, R. Immunotherapy for T1DM—still not there yet. Nat Rev Endocrinol 9, 697–698 (2013). https://doi.org/10.1038/nrendo.2013.221
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.221
